
US-based Traceability manufactures radiopharmaceuticals and offers automated solutions for PET and SPECT radiotracer testing.
Founded in Culver City, United States, Trace-Ability focuses on manufacturing radiopharmaceuticals for positron-emission tomography (PET) and single-photon emission computed tomography (SPECT). Their core mission is to enhance the quality control of radiotracers through automation and innovation. The company offers products like the Tracer-QC™, an automated solution utilizing optical plate readers, pipetting robots, and single-use consumable kits for release testing of PET and SPECT radiotracers, ensuring optimal cGMP compliance.
Notable figures affiliated with Trace-Ability include their leadership team and a dedicated scientific advisory board. The company has achieved significant milestones in automating radiopharmaceutical quality control, contributing to more reliable and efficient testing processes. Their impact is evident in the improved accuracy and traceability of radiotracer testing, benefiting both the medical imaging industry and patient outcomes.

BlueTrace
oystertracker.com

Trace Matters
tracematters.com

Trace Register

TrackX Technology
trackx.tech

Trace.Space
trace.space

TraceRx

InfiniTrak
infinitrak.us

Tag-N-Trac
tagntrac.com

Trace Labs
tracelabs.io

Tracer
tracer.tech

Antares Vision
antaresvision.com

Q-Track
q-track.com

121nexus
121nexus.com

Traceable
traceable.ai

TeleTracking Technologies
teletracking.com
Companies similar to Trace-Ability include BlueTrace, Trace Matters, Trace Register and TrackX Technology.
Trace-Ability was founded in 2013.
Trace-Ability's headquarters is located in Culver City, CA, US.
Trace-Ability's most recent funding round was for $1.1M (USD) in February 2016.
As of Feb 29, 2016, Trace-Ability has raised a total of $1.3M (USD).
Trace-Ability has 6 employees as of Feb 4, 2024.